Allogene Therapeutics Inc (ALLO) concluded trading on Wednesday at a closing price of $4.15, with 4.08 million shares of worth about $16.92 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -6.95% during that period and on Wednesday February 7 the price saw a gain of about 0.97%. Currently the company’s common shares owned by public are about 144.44M shares, out of which, 103.88M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 22 times over the past 12 months. They bought 6,234,994 shares in 16 of the transactions. In 6 selling transactions, insiders dumped 103,198 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the stock later moved at a day high price of 4.1900, or with a gain of 0.97%. Stock saw a price change of 17.90% in past 5 days and over the past one month there was a price change of 32.59%. Year-to-date (YTD), ALLO shares are showing a performance of 29.28% which decreased to -45.89% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.23 but also hit the highest price of $7.76 during that period. The average intraday trading volume for Allogene Therapeutics Inc shares is 3.13 million. The stock is currently trading 22.31% above its 20-day simple moving average (SMA20), while that difference is up 36.52% for SMA50 and it goes to 2.32% higher than SMA200.
Allogene Therapeutics Inc (NASDAQ: ALLO) currently have 144.44M outstanding shares and institutions hold larger chunk of about 62.53% of that.
The stock has a current market capitalization of $698.36M and its 3Y-monthly beta is at 0.73. It has posted earnings per share of -$2.24 in the same period. It has Quick Ratio of 12.58 while making debt-to-equity ratio of 0.17. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALLO, volatility over the week remained 9.82% while standing at 7.84% over the month.
Analysts are in expectations that Allogene Therapeutics Inc (ALLO) stock would likely to be making an EPS of -$0.45 in the current quarter, while forecast for next quarter EPS is -$0.44 and it is -$1.76 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.62 which is -$0.34 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.66 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 13.40% while it is estimated to increase by 12.87% in next year.
